Xalkori bags FDA green light for rare paediatric non-Hodgkin lymphoma
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
Read More
Tag: Xalkori
Alunbrig recommended by NICE for non-small-cell lung cancer
NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.
Read More
Takeda’s Alunbrig shows promise as first-line ALK NSCLC therapy
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Read More
Takeda’s Alunbrig beats Pfizer’s Xalkori on PFS in ALK positive NSCLC
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Read More
SMC approves funding for six new therapies on the NHS
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read More
Pfizer asked to submit CDF proposal for Xalkori
Pfizer’s Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer.
Read More
Pfizer’s lorlatinib impresses in Phase II lung cancer trial
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
Read More
Roche’s Alecensa beats Pfizer’s Xalkori in lung cancer trial
Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free survival in patients with a specific type of lung cancer.
Read More
NICE reappraisals back Novartis’ Afinitor and Pfizer’s Xalkori
Cancer patients will likely get routine access to Novartis’ Afinitor and Pfizer’s Xalkori on the NHS after a positive recommendation was handed down from the National Institute for Health and Care Excellence.
Read More
Pfizer’s Xalkori cleared for ROS1-positive lung cancer
The European Commission has widened the scope of Pfizer’s Xalkori to include the treatment of adults with ROS1-positive advanced non-small-cell lung cancer.
Read More
SMC clears use of five news drugs on NHS Scotland
Scottish cost regulators have endorsed the use of five new medicines by NHS Scotland, offering patients new options for lung cancer, depression, ankylosing spondylitis and epilepsy.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
